Driving under the influence of marijuana could soon become legal in Australia’s most populated state, but only for some ...

Rocket Science Health Corp., a Canadian drug delivery technology company, has been awarded U.S. Patent No. 12,403,275 by the United States Patent and Trademark Office for its fluid dynamics ...

Novartis has claimed a first-in-class regulatory approval in the US for oral BTK inhibitor remibrutinib as a second-line treatment for chronic spontaneous urticaria (CSU), also known as chronic hives.

Shares in Eli Lilly were tracking down this morning after the company revealed data on its oral weight-loss candidate, orforglipron, that seems to have once again disappointed investors. The results ...